Clinical efficacy of terbutaline combined with budesonide inhalation in the treatment of chronic obstructive pulmonary disease
特布他林联合布地奈德吸入治疗慢阻肺的临床疗效

摘要

目的 研究对慢阻肺患者应用实施特步他林联合布地奈德进行吸入治疗对临床疗效所展现的实施效果与实施价值。方法 本次研究的病例数为200例，他们均来自于2021年1月-2025年1月期间我院诊断收治的慢阻肺患者，根据奇偶数随机原则将其分为对照组和观察组，分别应用单一布地奈德雾化治疗方法和特步塔林联合布地奈德吸入治疗，并对两组患者的临床疗效、肺功能指标、血气指标对比进行评价分析。结果 经治疗后观察组的临床总有效率、肺功能指标及血气指标均更高，不良反应发生率和炎性因子均更低。组间数值P＜0.05，说明存在对比意义。结论 对慢阻肺患者在其治疗中应用实施特步塔林联合布地奈德进行吸入治疗其临床疗效显著，能够有效改善患者肺功能指标、血气指标，减少患者不良反应的发生情况，提高患者的生活质量和满意程度，值得在临床上进行推广。

Abstract

Objective To investigate the clinical efficacy and value of inhalation therapy of terbutaline combined with budesonide in patients with chronic obstructive pulmonary disease (COPD).
Methods The number of cases in this study was 200, all of whom were diagnosed and treated with chronic obstructive pulmonary disease (COPD) in our hospital from January 2021 to January 2025. They were randomly divided into a control group and an observation group according to the odd even principle, and treated with single budesonide nebulization therapy and terbutaline combined with budesonide inhalation therapy, respectively. The clinical efficacy, lung function indicators, and blood gas indicators of the two groups of patients were evaluated and analyzed.
Results After treatment, the clinical total effective rate, lung function indicators, and blood gas indicators of the observation group were higher, and the incidence of adverse reactions and inflammatory factors were lower. The inter group value P<0.05 indicates the existence of comparative significance.
Conclusion   The application of Terbutamol combined with Budesonide inhalation therapy in the treatment of patients with chronic obstructive pulmonary disease has significant clinical efficacy, which can effectively improve patients' lung function indicators, blood gas indicators, reduce the occurrence of adverse reactions, and improve patients' quality of life and satisfaction. It is worth promoting in clinical practice.